A5080090641- Viral-associated cancers and disorders
- HIV Research and Treatment
- SARS-CoV-2 and COVID-19 Research
- Cytomegalovirus and herpesvirus research
- Lymphoma Diagnosis and Treatment
- Herpesvirus Infections and Treatments
- Parvovirus B19 Infection Studies
- COVID-19 Clinical Research Studies
- vaccines and immunoinformatics approaches
- Immunotherapy and Immune Responses
- T-cell and Retrovirus Studies
- Polysaccharides and Plant Cell Walls
- Immune Cell Function and Interaction
- Protein Tyrosine Phosphatases
- Histiocytic Disorders and Treatments
- Chronic Lymphocytic Leukemia Research
- Complement system in diseases
- HIV/AIDS Research and Interventions
- COVID-19 epidemiological studies
- HIV/AIDS drug development and treatment
- COVID-19 Impact on Reproduction
- Monoclonal and Polyclonal Antibodies Research
Bionor (Denmark)
2013-2014
Bionor (Norway)
2012
Mora lasarett
1994
Karolinska Institutet
1987-1992
Spike-specific antibodies are central to effective COVID19 immunity. Research efforts have focused on that neutralize the ACE2-Spike interaction but not non-neutralizing antibodies. Antibody-dependent phagocytosis is an immune mechanism enhanced by opsonization, where typically, more bound trigger a stronger phagocyte response. Here, we show antibodies, dependent concentration, can either enhance or reduce Spike-bead monocytes independently of antibody neutralization potential. Surprisingly,...
Antibodies play a central role in the immune defense against SARS-CoV-2. Emerging evidence has shown that nonneutralizing antibodies are important for through Fc-mediated effector functions. Antibody subclass is known to affect downstream Fc function. However, whether antibody plays anti-SARS-CoV-2 immunity remains unclear. Here, we subclass-switched eight human IgG1 anti-spike monoclonal (mAbs) IgG3 by exchanging their constant domains. The mAbs exhibited altered avidities spike protein and...
Abstract Four monoclonal and one polyclonal lymphoblastoid cell line (LCL) were studied with regard to cytoplasmic immunoglobulin (clg) expression, presence of the Epstein‐Barr virus (EBV)‐determined nuclear antigen (EBNA) DNA synthesis. Each was found consist two subpopulations, only minimal overlap. Proliferating, EBNA‐positive, clg‐negative cells formed majority. The minority EBNA‐negative, contained abundant clg largely non‐proliferating. This suggests continuous occurrence a maturation...
Abstract The Epstein‐Barr virus (EBV) nuclear antigen 2 (EBNA‐2) is the only one of EBNA proteins to have been implicated as an EBV‐encoded transforming protein. More detailed studies this protein hampered by lack EBNA‐2‐specific monoclonal antibodies (MAbs) and purified To overcome these problems, we isolated 5 hybridomas producing MAbs reactive with 18 residue synthetic peptide corresponding carboxyterminus EBNA‐2. Four were specifically EBNA‐2 in its denatured form on immunoblots. 5th...
ABSTRACT Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCLs) express at least seven virally encoded proteins. Their functional role, and their relationships to each other normal nuclear constituents are virtually unknown. As the first step towards a topographical study, intranuclear distribution of EBV-encoded antigens EBNA-1, -2, -3 -5 (abbreviated El, E2 etc.) was examined in EBV-transformed LCLs by immunofluorescence digital image analysis fluorescence patterns. E1-E3...
Spike-specific antibodies are central to effective COVID19 immunity. Research efforts have focused on that neutralize the ACE2-Spike interaction but not non-neutralizing antibodies. Antibody-dependent phagocytosis is an immune mechanism enhanced by opsonization, where typically, more bound trigger a stronger phagocyte response. Here, we show antibodies, dependent concentration, can either enhance or reduce Spike-bead monocytes independently of antibody neutralization potential. Surprisingly,...
Results For subjects that remained off ART until week 52 (Vacc-4x n=56, placebo n=25), there was a log 0.44 reduction in viral load set point between the Vacc-4x and groups (p=0.0397). There similar distribution of HLA class I alleles two treatment arms, with exception B35 allele (27% versus 8% subjects). The ELISPOT positive significantly lower than (p=0.023). no significant difference T-cell proliferation responses groups, however, percentage showing proliferative CD4 CD8 to peptides...
Abstract Three Epstein‐Barr‐virus‐transformed lymphoblastoid cell lines (LCL) were analysed on the basis of their CD23 expression. Levels EBV‐DNA compared in positive and negative subpopulations. Two further with regard to EBNA, cytoplasmic immunoglobulin (clg) lytic (EA/VCA) protein Both subpopulations had a similar MHC class‐11 transcription, but − subpopulation lower plating efficiency rate DNA synthesis. In B6, NAD50 0467.3 lines, cells contained 2 ± 0.2–6.4 3.0 times less EBV than...
Immune-based interventions for HIV-1 infection need to achieve both the induction of effective anti-viral responses as well a reduction in HIV-associated hyperactivation immune system. Vacc-4x is peptide-based therapeutic vaccine designed induce cytotoxic T-cell-based killing HIV-infected cells. has recently completed large phase II study Europe and USA enrolling 135 subjects (www.clinicaltrials.gov identifier NCT00659789). Subjects that achieved 6 month ART-free period showed statistically...